Neurocrine Biosci receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc stock price live, this page displays NASDAQ NBIX stock exchange data. View the NBIX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Neurocrine Biosciences Inc real time stock price chart below.
What Is the Neurocrine Biosciences Inc Stock Price Today?
The Neurocrine Biosciences Inc stock price today is 138.60.
What Is the Stock Symbol for Neurocrine Biosciences Inc?
The stock symbol for Neurocrine Biosciences Inc is ""NBIX.""
What Stock Exchange Does Neurocrine Biosciences Inc Trade On?
Neurocrine Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Neurocrine Biosciences Inc a Good Stock to Buy?
Determining whether Neurocrine Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NBIX quote. (ISIN: US64125C1099)
What Is the Neurocrine Biosciences Inc Stock Price Today?
The Neurocrine Biosciences Inc stock price today is 138.60.
What Is the Stock Symbol for Neurocrine Biosciences Inc?
The stock symbol for Neurocrine Biosciences Inc is ""NBIX.""
What Stock Exchange Does Neurocrine Biosciences Inc Trade On?
Neurocrine Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Neurocrine Biosciences Inc a Good Stock to Buy?
Determining whether Neurocrine Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NBIX quote. (ISIN: US64125C1099)
138.60
+1.60(+1.17%)
Real-time Data·
Fair Value
An estimate of a Neurocrine's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
136.10
138.88
52 wk Range
84.23
154.61
NBIX Scorecard
Full Analysis
Management has been aggressively buying back shares
NBIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Neurocrine's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
136.10138.88
52 wk Range
84.23154.61
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NBIX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Neurocrine's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
168.94
Upside
+21.89%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Neurocrine Biosciences Inc Company Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences Inc SWOT Analysis
Ingrezza's Dominance | Explore Neurocrine's reliance on Ingrezza, its primary revenue driver, and the drug's consistent performance amidst market challenges and expansion efforts |
Crenessity's Potential | Delve into the recent approval of Crenessity for CAH and its projected peak sales of $800M-$1B, marking a significant milestone for Neurocrine's portfolio |
Pipeline Promise | Learn about Neurocrine's robust pipeline, including Phase 3 trials for Ingrezza in new indications and NBI-770 for depression, driving future growth prospects |
Market Valuation | Analysts set price targets ranging from $115 to $190, with an average around $152, reflecting varied perspectives on Neurocrine's growth and market position |
Neurocrine Biosciences Inc Earnings Call Summary for Q2/2025
- Q2 2025 net product sales up 17% YoY to $682M; INGREZZA sales rose 8% to $624M with record new patient starts
- Prenepsi sales surged from $15M in Q1 to $53M in Q2; company has $1.8B cash on hand
- INGREZZA net sales guidance refined to $2.5B-$2.55B; SG&A guidance increased by $25M
- Stock dipped 0.45% premarket despite 43% gain over past 6 months; trading below Fair Value per InvestingPro
- R&D Day planned for December 16th to discuss pipeline and strategic initiatives
Last Updated: 06/10/2025, 16:28
Read Full TranscriptCompare NBIX to Peers and Sector
Metrics to compare | NBIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNBIXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 39.2x | −5.0x | −0.7x | |
PEG Ratio | 13.12 | 0.92 | 0.00 | |
Price/Book | 5.1x | 0.8x | 2.6x | |
Price / LTM Sales | 5.4x | 41.4x | 3.4x | |
Upside (Analyst Target) | 24.1% | 157.7% | 35.7% | |
Fair Value Upside | Unlock | 16.1% | 4.1% | Unlock |
Analyst Ratings
23 Buy
3 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 168.94
(+21.89% Upside)
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
1.65 / 0.96
Revenue / Forecast
687.50M / 653.32M
People Also Watch
FAQ
What Stock Exchange Does Neurocrine Trade On?
Neurocrine is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Neurocrine?
The stock symbol for Neurocrine is "NBIX."
What Is the Neurocrine Market Cap?
As of today, Neurocrine market cap is 13.73B.
What Is Neurocrine's Earnings Per Share (TTM)?
The Neurocrine EPS (TTM) is 3.39.
When Is the Next Neurocrine Earnings Date?
Neurocrine will release its next earnings report on 03 Nov 2025.
From a Technical Analysis Perspective, Is NBIX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Neurocrine Stock Split?
Neurocrine has split 0 times.
How Many Employees Does Neurocrine Have?
Neurocrine has 1800 employees.
What is the current trading status of Neurocrine (NBIX)?
As of 08 Oct 2025, Neurocrine (NBIX) is trading at a price of 138.60, with a previous close of 137.00. The stock has fluctuated within a day range of 136.10 to 138.88, while its 52-week range spans from 84.23 to 154.61.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.